¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"beta interferon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
  • beta-carotene
    º£Å¸Ä«·Îƾ
  • beta-lactam
    º£Å¸¶ôŽ
  • beta-lactamase
    º£Å¸¶ô޾ÆÁ¦
  • beta-lactamase inhibitors
    º£Å¸¶ô޾ÆÁ¦¾ïÁ¦Á¦
  • pre-beta-lipoprotein
    ÇÁ¸®º£Å¸ÁöÁú´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • interferon-¥á (INF-¥á)
    ¾ËÆÄÀÎÅÍÆä·Ð
  • interferon-¥â (INF-¥â)
    º£Å¸ÀÎÅÍÆä·Ð
  • interferon-¥ã (INF-¥ã)
    °¨¸¶ÀÎÅÍÆä·Ð
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • beta (¥â) chain
    º£Å¸»ç½½, º£Å¸¼â
  • beta (¥â) globulin
    º£Å¸±Û·ÎºÒ¸°
  • beta (¥â) hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta (¥â) lysin
    º£Å¸¿ëÇ÷¼Ò, ¿ÏÀü¿ëÇ÷¼Ò
  • beta (¥â) microglobulin
    º£Å¸¹ÌÅ©·Î±Û·ÎºÒ¸°
  • beta (¥â)-lactam
    º£Å¸¶ôŽ
  • beta (¥â)-lactam antibiotic
    º£Å¸¶ôŽ Ç×»ýÁ¦
  • beta (¥â)-lactamase
    º£Å¸¶ôŸ¸¶Á¦, º£Å¸¶ôŽ °¡¼öºÐÇØÈ¿¼Ò
  • beta (¥â)-lactamase inhibitor
    º£Å¸¶ôŸ¸¶Á¦¾ïÁ¦Á¦
  • beta =¥â
    º£Å¸.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • beta galactosidase
    º£Å¸ °¥¶ôÅä½Ãµ¥À̽º
  • beta galactoside permease
    º£Å¸ °¥¶ôÅä»çÀÌµå ÆÛ¸£¹Ì¿¡À̽º
  • beta glucosidase
    º£Å¸ ±Û·çÄڽõ¥À̽º
  • beta glucuronidase
    º£Å¸ ±Û·çÅ¥·Î´Ïµ¥À̽º
  • beta keratin
    º£Å¸ Äɶóƾ
  • beta lactam antibiotics
    º£Å¸ ¶ôŽ Ç×»ýÁ¦(ù÷ßæð¥)
  • beta lactamase
    º£Å¸ ¶ôŸ¸ÞÀ̽º
  • beta lactoglobulin
    º£Å¸ ¶ôÅä±Û·ÎºÒ¸°
  • beta lipoprotein
    º£Å¸ ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • beta meander
    º£Å¸ ±¼°î(ÏÝÍØ)
  • beta orientation
    º£Å¸ ¹èÀ§(ÛÕêÈ)
  • beta oxidation
    º£Å¸ »êÈ­(ß«ûù)
  • beta particle
    º£Å¸ ÀÔÀÚ(Ø£í­)
  • beta plateau
    º£Å¸ ÇöóÅä
  • beta ray
    º£Å¸¼±(àÊ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
INF-¥ã Interferon-¥ã
FIF feedback inhibition factor; fibroblast interferon; forced inspiratory flow; formaldehyde-induced flu...
HFI hereditary fructose intolerance; human fibroblast interferon
HFIF human fibroblast interferon
HLBI human lymphoblastoid interferon
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
3 beta-diol alpha-Androstane-3 beta,17 beta-diol
IFNbeta1b Interferon beta 1B
IFNbeta-1a Interferon beta-1a
IFN beta-Interferon
beta-glucan 1----3)-beta-D-glucan
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • beta-endorphin immunoreactivity
    º£Å¸ ¿£µµ¸£ÇÉ ¸é¿ª ¹ÝÀÀ
  • beta-lactam antibiotics
    º£Å¸-¶ôŽ Ç×»ýÁ¦
  • beta-lipoprotein
    º£Å¸ Áö¹æ ´Ü¹é
    Ç÷Áß ÁöÁú·Î Ư¼öÇÑ ¾ÆÆ÷ ´Ü¹éÀÌ °áÇÕµÈ °ÍÀ» ¸®Æ÷ ´Ü¹éÀ̶ó°í Çϴµ¥ ±× Áß¿¡¼­ Àü±â¿µµ¿¿¡ ÀÇÇØ¼­ º£Å¸ ±Û·ÎºÒ¸°ÀÇ ºÎÀ§¿¡ °ËÃâµÇ´Â °Í.
  • beta-titanium
    º£Å¸ ƼŸ´½
  • dopamine-beta-hyroxylase
    µµÆÄ¹Î º£Å¸ È÷µå·Ï½Ç¶óÁ¦
  • hypothalamic beta-endorphin neuron
    ½Ã»ó ÇϺÎÀÇ º£Å¸-¿£µ¹ÇÉ ´º¿ì·±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
fibroblast interferon <cytokine> One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
Synonym: fibroblast interferon.
Pharmacological action: adjuvants, immunologic, antineoplastic agent, antiviral agents.
Chemical name: Interferon-alphaB (human leukocyte protein moiety reduced)
(12 Dec 1998)
leukocyte interferon <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products.
It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia.
A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents.
See: interferon-alpha 2a, interferon-alpha 2b
Synonym: leukocyte interferon.
Pharmacological action: antineoplastic agent, antiviral agent.
(20 Sep 2002)
androst-5-ene-3 beta,17 beta-diol <chemical> An adrenal-derived oestrogenic metabolite of dhea. Evidence exist for its use as an endocrine regulator of immune response.
Pharmacological action: anabolic steroids.
Chemical name: Androst-5-ene-3,17-diol, (3beta,17beta)-
(12 Dec 1998)
beta-1,3-galactosyl-0-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase <enzyme> Capable of adding a glcnac residue to g1cnacman(3)g1cnac; from mung bean seedlings
Registry number: EC 2.4.1.146
Synonym: n-acetylglucosaminyltransferase II, gal3-(glcnac6)galnac-mucin (glcnac--gal)3-glcnactransferase
(26 Jun 1999)
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase <enzyme> With EC 2.4.1.148 this is called beta6-glcnac-transferase b
Registry number: EC 2.4.1.102
Synonym: gal3-galnac-mucin-6-glcnac transferase, udp-glcnac-gal1-3galnac-r-(glcnac to galnac)-beta1-6glcnac transferase, core 2 glcnac transferase, core 2-n-acetylglucosaminyltransferase, core 2 beta6-gn-t
(26 Jun 1999)
beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase <enzyme> Induced in preneoplastic stage of liver carcinogenesis promoted by orotic acid in rats; adds "bisecting n-acetylglucosaminyl residue in beta 1,4 linkage to the beta-linked mannose of the core of asparagine-linked oligosaccharides
Registry number: EC 2.4.1.144
Synonym: n-acetylglucosaminyltransferase III, udpgnac-glycopeptide beta4-n-acetylglucosaminyl transferase III, udpgnac-magtransferase III, udp-n-acetylglucosamine-beta-d-mannoside beta-1,4-n-acetylglucosaminyltransferase III
(26 Jun 1999)
beta-hydroxy-beta-methylglutaryl-CoA -OOCCH2C(OH)(CH3)CH2COS-CoA;a key intermediate in the synthesis of ketone bodies and of steroids.
Synonym: 3-hydroxy-3-methylglutaryl-CoA.
Beta-hydroxy-beta-methylglutaryl-lyase, an enzyme, found primarily in liver and rumen epithelium that catalyses the formation of acetyl-CoA and acetoacetate from beta-hydroxy-beta-methylglutaryl-CoA; a key step in ketogenesis; a deficiency of this enzyme leads to episodes of severe metabolic acidosis without ketosis.
Beta-hydroxy-beta-methylglutaryl-reductase, an enzyme that catalyses the rate-limiting step of cholesterol biosynthesis, beta-hydroxy-beta-methylglutaryl-CoA + 2NADPH + 2H+ &rarr; mevalonate + 2NADP+ + coenzyme A.
Beta-hydroxy-beta-methylglutaryl-synthase, an enzyme in mitochondria that catalyses the reaction of acetyl-CoA with acetoacetyl-CoA and water to form beta-hydroxy-beta-methylglutaryl-CoA and coenzyme A, a step required for both ketogenesis and steroidogenesis to occur.
(05 Mar 2000)
beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase <enzyme> An enzyme that catalyses the transfer of galactose from udp-galactose to a specific glycoprotein receptor, 2-acetamido-2-deoxy-d-glucosyl-glycopeptide, during glycopeptide synthesis.
Chemical name: UDPgalactose:N-acetyl-beta-D-glucosaminylglycopeptide beta-1,4-galactosyltransferase
Registry number: EC 2.4.1.38
(12 Dec 1998)
beta, or beta-value <radiobiology> Ratio of plasma kinetic pressure to magnetic-field pressure, proportional to the ratio of plasma kinetic energy density to magnetic field energy density. Beta is usually measured relative to the total, local field (loosely called beta toroidal), but sometimes the plasma pressure relative to only the poloidal component of the field (beta poloidal) or relative to some external field (like the maximum field at the magnetic coils) is more useful. There is also a normalised beta (beta_N) of interest when discussing the beta limit. (lots of help from Art Carlson with the above.) Because the cost of a reactor is strongly influenced by the strength of the magnetic field that must be provided, beta values are directly related to the economics of fusion power production. Beta is usually expressed as a percentage, with 5% generally believed to be the minimum value required for an economical fusion reactor.
See: pressure, kinetic pressure, magnetic pressure, second stability.
(09 Oct 1997)
UDP-GalNAc-beta-galactose beta 1,4-N-acetylgalactosaminyltransferase <enzyme> Consider also EC 2.4.1.92
Registry number: EC 2.4.1.-
Synonym: beta-1,4-n-acetylgalactosaminyltransferase, 4-galnactransferase, udp-n-acetylgalactosamine-beta-galactose beta 1,4-n-acetylgalactosaminyltransferase, (1-4)-n-acetyl-beta-d-galactosaminyltransferase, galnact-1
(26 Jun 1999)
5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostatic microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 6 alpha-hydroxylase
(26 Jun 1999)
5 alpha-androstane 3 beta,17 beta-diol 7 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostate microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 7 alpha-hydroxylase
(26 Jun 1999)
acetyl CoA-(beta-aminoethyl)-L-cysteine omega-N-acetyltransferase <enzyme> Forms s-(beta-n-acetyl-aminoethyl)-l-cysteine
Registry number: EC 2.3.1.-
Synonym: acoac-acetyltransferase, acetyl coenzyme a-(beta-aminoethyl)-l-cysteine omega-n-acetyltransferase
(26 Jun 1999)
acetylgalactosaminylgalactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase <enzyme> Forms galnac-beta1-3galnac-beta1-3gal-alpha1-4gal-beta1-4glc-cer
Registry number: EC 2.4.1.-
Synonym: forssman glycolipid synthase, udp-galnac globotetraoside n-acetylgalactosaminyl transferase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á